SCHEMBL3347455

SCHEMBL3347455

CCCCCCCCNN=O

nearest known ligand 0.54

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 8/20 0.54
ADH1B P00325 2/20 0.54
ADH1C P00326 2/20 0.54
ADH1A P07327 2/20 0.54
ADH7 P40394 2/20 0.54
ADH4 P08319 1/20 0.54
TSHR P16473 2/20 0.46
ALDH1A1 P00352 1/20 0.46
PPARA Q07869 2/20 0.43
THRB P10828 1/20 0.42
GBA1 P04062 3/20 0.41
CASP2 P42575 1/20 0.41
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6556648 1.00 EPHX1 (0.54) EPHX1ADH1BADH1CADH1AADH7
SCHEMBL11861192 1.00 EPHX1 (0.54) EPHX1ADH1BADH1CADH1AADH7
SCHEMBL9008392 1.00
SCHEMBL2841962 1.00 EPHX1 (0.54) EPHX1ADH1BADH1CADH1AADH7
SCHEMBL17873409 1.00 EPHX1 (0.54) EPHX1ADH1BADH1CADH1AADH7
SCHEMBL14237059 1.00 EPHX1 (0.54) EPHX1ADH1BADH1CADH1AADH7
SCHEMBL9485078 1.00 EPHX1 (0.54) EPHX1ADH1BADH1CADH1AADH7
SCHEMBL10749074 0.97
SCHEMBL4936672 0.89
SCHEMBL7214020 0.87 FAAH (0.57) EPHX1ADH1BADH1CADH1AADH7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242495-A1 Nitrosation Reagents and Methods THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-08-03 US disclosed
US-20230242495-A1 Nitrosation Reagents and Methods THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-08-03 US disclosed
WO-2021257849-A1 NITROSATION REAGENTS AND METHODS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-12-23 WO disclosed
US-20160369237-A1 METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY ADVANCED CELL TECH INC (US) 2016-12-22 US disclosed
US-20100184033-A1 METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY Lineage Cell Therapeutics, Inc. 2010-07-22 US disclosed
US-20100162416-A1 Multi-stage stem cell carcinogenesis STEMLIFELINE, INC. (US) 2010-06-24 US disclosed
WO-2010037134-A2 MULTI-STAGE STEM CELL CARCINOGENESIS STEMLIFELINE, INC. (US) 2010-04-01 WO disclosed
US-20080226601-A1 Herpes Virus-Based Compositions and Methods of Use in the Prenatal and Perinatal Periods UNIVERSITY OF ROCHESTER (US) 2008-09-18 US disclosed
US-20080070303-A1 Using myocardial and/or muscle progenitor cells as modeling tool in tissue engineering; regenerative medicine and organ replacement ADVANCED CELL TECHNOLOGY 2008-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242495-A1 Nitrosation Reagents and Methods NOS2, NOS1, NNMT EPHX1 1269/4885ADH1B 295/4885ADH1C 227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.